Glenmark pharma corona medicine approval

Glenmark Pharmaceuticals got Apporoval for Corona treatment medicine

Glenmark Pharmaceuticals ltd has received the manufacturing and marketing approval from India's drug regulator to launch the oral antiviral drug Favipiravir for the treatment of mild to moderate COVID 19  patients in India. Thus Glenmark becomes the first pharmaceutical  company in India to receive such approval. 

Effect of medicine on COVID patient

According to Glenmark, its antiviral drug Favipiravir had shown clinical improvement of upto 88 percent in mild to moderate COVID 19 cases. 

However it is said that pregnant and lactating mothers are not included in the clinical trial.

Launching of Favipiravir

The domestic Pharmaceutical company announced the launch of the first oral Favipiravir in the brand name Fabiflu. The antiviral offers broad spectrum coverage with clinical improvement across age groups 20 to 90 years. 

Favipiravir can be used patients with morbid conditions such as diabetes and heart disease with mild to moderate covid 19 symptoms.

The statement is released by Pharma company " It offers rapid reduction in viral load within 4 days and provides faster symptomatic improvement.

ANI had reported that the country's top drug has generated permission to antiviral drug favipiravir for restricted emergency use in mild to moderate cases of COVID 19 in India.

About Fabiflu

Fabiflu is developed by glenmark pharma through its in house Research and development team. It is orally administered and so it serves as a more convenient teeatment option rather than other administered medications.

Notably Flavipavir has been approved in Japan since 2014 for the treatment of influenza virus infections. 

The drug will be available as a prescription based medication for 103 rs per tablet with the recomended dose being 180 mg twice daily on day 1 followed by 800 mg twice daily upto day 14.

The company hopes that the availability of an effective treatment such as Fabiflu will cosiderably help assauge the presure and offer patients in India a much needed and timely therapy option.

About Glenmark pharmaceuticals ltd

Glenmark Pharmaceuticals is a pharma company headquarted in Mumbai, India. It was founded in 1977 by Gracious Saldanha as a genetic drug manufacturer. He named the company after his sons. The company initially sold its products in India, Russia and Africa. The company went public in India in 1999 and proceeded to build its first research facility. By 2008, Glenmark was the fifth largest pharmaceutical company in India. By 2011, founder of the company was one of the richest man in India. The growth was driven by Glenmark entry into US and European generics markets.